Cristina Nanni on Flucicovine F18 (FACBC) in Prostate Cancer - State of the Art Presentation
July 13, 2016
For More information of the use of F18 in the diagnosis of recurrent prostate cancer:
SNMMI 2016: Fluciclovine F18 (FACBC): An Amino Acid Tracer for the Staging of Recurrence Prostate Cancer
FDA Approval of Axumin™ (Flucicovine F18 (FACBC)
18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.
Cristina Nanni, MD.
Dr. Cristina Nanni is a Nuclear Medicine Physician working at the PET Centre in Bologna (ITALY) since 2007.
She got her residency in Nuclear Medicine at the University Bologna (2000 to 2004) and in Radiology in 2012. She worked in the field of pre-clinical PET imaging in 2005 and 2006. Now she is responsible for new radiotracers applications and integration of morphological and functional imaging (PET/ceCT and PET/CT guided biopsy) in the clinical practice.
Recently she is been working on the application of FACBC as an alternative tracer beside Choline in prostate cancer patients.
She is author and co-author of 190 clinical and pre-clinical papers published in international journals and more than 200 abstracts presented at national and international congresses as posters and oral presentations.
Phillip Koo, MD